Acurx is a no-revenue antibiotic developer with a Phase 3-ready CDI lead asset, a new recurrent-CDI pilot plan, repeated equity financing, and explicit going-concern pressure. The question is whether ibezapolstat gets financed into proof before dilution becomes the main story.
References
Sources used in this report
SEC APISEC submissions JSON2026-05-14 · Company identity, CIK, ticker, exchange, headquarters, SIC, and filing sequence.SEC APISEC companyfacts JSON2026-05-14 · XBRL cross-check for financial statements, cash use, financing cash flow, equity, and share data.SEC filingFY2025 Form 10-K2026-03-12 · Business overview, pipeline, competition, risks, financing history, going concern, financials, compensation, and ownership.SEC filingQ1 2026 Form 10-Q2026-05-11 · Latest quarterly financials, cash, balance sheet, accumulated deficit, share count, offering update, and going concern.SEC-filed releaseRecurrent-CDI program release2026-03-09 · rCDI pilot plan, Phase 2 results, Phase 3 readiness, regulatory-designation claims, and clinical development timing.SEC filingApril 2026 offering Form 8-K2026-04-16 · Registered direct offering, private placement warrants, purchase agreement, and use-of-proceeds framework.SEC filingApril 2026 offering prospectus supplement2026-04-16 · Pricing, gross proceeds, placement-agent fees, prefunded warrants, and dilution mechanics.SEC filingMay 2026 Lincoln Park resale prospectus2026-05-12 · Resale shares, ELOC context, additional potential proceeds, reverse split note, and recurrent-CDI update.SEC filing2025 annual meeting proxy2025-05-29 · Governance, annual meeting, compensation, reverse split proposal, equity-plan increase, and financing approvals.Regulator sourceFDA LPAD pathway2026-05-14 · Regulatory context for the Limited Population Pathway referenced by Acurx.Government sourceCDC About C. diff2026-05-14 · Public-health context for C. diff and infection-control relevance.